Cancer immunotherapy

Kineta Enters Research Collaboration and License Agreement with Pfizer to Develop New Cancer Immunotherapies

Retrieved on: 
Monday, December 17, 2018
Medicine, Health, Virotherapy, Cancer treatments, Oncology, Cancer immunotherapy, Pfizer, Immunotherapy, Kineta, PFE

SEATTLE, Dec. 17, 2018 /PRNewswire/ -- Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with Pfizer Inc. (NYSE:PFE) to develop RIG-I agonist immunotherapies for the treatment of cancer.

Key Points: 
  • SEATTLE, Dec. 17, 2018 /PRNewswire/ -- Kineta Immuno-Oncology, LLC (KIO), a subsidiary of Kineta, Inc., today announced that it has entered into a strategic research collaboration with Pfizer Inc. (NYSE:PFE) to develop RIG-I agonist immunotherapies for the treatment of cancer.
  • The research collaboration and license agreement grants to Pfizer the exclusive rights to KIO's RIG-I screening platform and related compounds and technologies.
  • Additionally, the compounds have demonstrated synergistic effects when used in combination with other immunotherapies like checkpoint inhibitors.
  • We are very enthusiastic about this new cancer immunotherapy collaboration, which represents the second major partnering transaction for Kineta this year."

NOVADIP BIOSCIENCES appoints Jeff Abbey as CEO

Retrieved on: 
Wednesday, December 12, 2018
Biology, Biotechnology, Nature, Biopharmaceutical, Stem cell, Adipose tissue, Cancer immunotherapy

Mr. Abbey will join Novadip after more than 15 years at Argos Therapeutics, Inc., an immuno-oncology cell therapy company, including serving as president and chief executive officer for the past eight years.

Key Points: 
  • Mr. Abbey will join Novadip after more than 15 years at Argos Therapeutics, Inc., an immuno-oncology cell therapy company, including serving as president and chief executive officer for the past eight years.
  • "I am excited to have the opportunity to join Novadip," said Jeff Abbey.
  • The creation of Novadip Biosciences was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II.
  • Novadip Biosciences pioneers the growth of 3-dimensional biologics based on adipose-derived stem cells (ASC), to regenerate hard and soft tissues.

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

Retrieved on: 
Tuesday, December 11, 2018
Biotechnology, Immunology, Nature, Monoclonal antibodies, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Cancer immunotherapy, Bispecific monoclonal antibody

"Our immuno-oncology (IO) collaboration with WuXi Biologics, around the WuXiBody bispecific platform and clinical mid-stage PD-L1 antibody, is a significant step for OBT to deepen and broaden our exciting first-in-class IO pipeline," said Dr. Christian Rohlff, Chief Executive Officer of Oxford BioTherapeutics.

Key Points: 
  • "Our immuno-oncology (IO) collaboration with WuXi Biologics, around the WuXiBody bispecific platform and clinical mid-stage PD-L1 antibody, is a significant step for OBT to deepen and broaden our exciting first-in-class IO pipeline," said Dr. Christian Rohlff, Chief Executive Officer of Oxford BioTherapeutics.
  • "We are excited to expand our strategic partnership with OBT to include the proprietary WuXiBody platform.
  • WuXi Biologics will continue to invest to develop next-generation globally leading technologies to transform biologics discovery, development and manufacturing."
  • WuXiBody, a proprietary bispecific antibody platform of WuXi Biologics, is potentially the Best-in-Class bispecific platform in the field.

Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

Retrieved on: 
Tuesday, December 11, 2018
Biotechnology, Immunology, Nature, Monoclonal antibodies, Biopharmaceutical, Pharmaceutical industry, Pharmacy, Cancer immunotherapy, Bispecific monoclonal antibody

"Our immuno-oncology (IO) collaboration with WuXi Biologics, around the WuXiBody bispecific platform and clinical mid-stage PD-L1 antibody, is a significant step for OBT to deepen and broaden our exciting first-in-class IO pipeline," said Dr. Christian Rohlff, Chief Executive Officer of Oxford BioTherapeutics.

Key Points: 
  • "Our immuno-oncology (IO) collaboration with WuXi Biologics, around the WuXiBody bispecific platform and clinical mid-stage PD-L1 antibody, is a significant step for OBT to deepen and broaden our exciting first-in-class IO pipeline," said Dr. Christian Rohlff, Chief Executive Officer of Oxford BioTherapeutics.
  • "We are excited to expand our strategic partnership with OBT to include the proprietary WuXiBody platform.
  • WuXi Biologics will continue to invest to develop next-generation globally leading technologies to transform biologics discovery, development and manufacturing."
  • WuXiBody, a proprietary bispecific antibody platform of WuXi Biologics, is potentially the Best-in-Class bispecific platform in the field.

Immuno-oncology Development Trends and Opportunities

Retrieved on: 
Thursday, December 6, 2018
Cancer immunotherapy

"Immuno-oncology Development Trends and Opportunities", report provides an overview of current clinical development trends for Immuno-Oncology (IO) within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including a history of recent approvals, indications currently being explored for Immuno-Oncology (IO) agents of all modalities, targets being selected for Immuno-Oncology (IO) therapies, and combination strategies being investigated for approved Immuno-Oncology (IO) agents.

Key Points: 
  • "Immuno-oncology Development Trends and Opportunities", report provides an overview of current clinical development trends for Immuno-Oncology (IO) within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including a history of recent approvals, indications currently being explored for Immuno-Oncology (IO) agents of all modalities, targets being selected for Immuno-Oncology (IO) therapies, and combination strategies being investigated for approved Immuno-Oncology (IO) agents.
  • In addition, the report provides disease overviews, epidemiology, current recommended treatment regimens and Immuno-Oncology (IO) approvals, and Immuno-Oncology (IO) clinical trial trends for 17 indications identified on the basis of representing the largest commercial opportunities for Immuno-Oncology (IO) agents.
  • Clinical trial trends analyze ongoing trials by sponsor type and modality, as well as ongoing combination trials for approved Immuno-Oncology (IO) therapies.
  • - Drive revenues by understanding the key trends, innovative combination strategies and indications likely to impact the IO market in the future.

Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche

Retrieved on: 
Tuesday, December 4, 2018
Medicine, Immune system, Immunology, Cancer treatments, Cancer immunotherapy, Checkpoint inhibitor, Immunotherapy, Immune checkpoint, Monoclonal antibody, Active immunotherapy, Monoclonal antibody therapy

The global Cancer Immunotherapy market reached USD 42,584.18 Million in 2017 by registering a CAGR of 7.5% across the globe.

Key Points: 
  • The global Cancer Immunotherapy market reached USD 42,584.18 Million in 2017 by registering a CAGR of 7.5% across the globe.
  • Increasing technological innovations in Cancer Immunotherapy is also expected to impel the growth of Cancer Immunotherapy market in the North America.
  • Global Cancer Immunotherapy market is segmented on the basis of technology into Cellular Immunotherapy, Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cancer Vaccines & Cytokine Therapy.
  • Pfizer, Merck, Amgen and Roche are some of the prominent players of Cancer Immunotherapy market.

CAR T-Cell Therapies Show Durable Responses, New Research Also Explores Combination Therapies to Extend and Enhance Treatment Responses

Retrieved on: 
Monday, December 3, 2018
Medicine, Biology, Health, Cancer treatments, Biotechnology, Cell biology, Chimeric antigen receptor, Immune system, Therapy, Cell therapy, Tumor-infiltrating lymphocytes, Cancer immunotherapy

For example, CAR T cells may stop working in some patients for various reasons, which has prompted researchers to ask what combination therapies could be used to extend the benefits of treatment."

Key Points: 
  • For example, CAR T cells may stop working in some patients for various reasons, which has prompted researchers to ask what combination therapies could be used to extend the benefits of treatment."
  • Another success, according to researchers, is that the many centers in the study have been able to safely and consistently administer CAR T-cell therapy.
  • Nearly half of these patients required treatment in the intensive care unit for a median of seven days.
  • Twenty-five deaths were reported after CAR-T infusion, mostly due to disease progression and other causes unrelated to CAR T-cell therapy.

The global immune checkpoint inhibitors market was valued at $10,540 million in 2017, and is projected to reach $65,427 million by 2025, registering a CAGR of 25.6% from 2018 to 2025

Retrieved on: 
Thursday, November 29, 2018
Medicine, Immune system, Immunology, Clinical medicine, Immune checkpoint, PD-L1, Programmed cell death protein 1, Checkpoint inhibitor, T cell, CTLA-4, PD-1 and PD-L1 inhibitors, Cancer immunotherapy

Immune checkpoint inhibitor drugs block different checkpoint proteins, including cytotoxic T lymphocyte associated protein 4 (CTLA-4), programmed cell death protein (PD-1), and programmed death ligand 1 (PD-L1).

Key Points: 
  • Immune checkpoint inhibitor drugs block different checkpoint proteins, including cytotoxic T lymphocyte associated protein 4 (CTLA-4), programmed cell death protein (PD-1), and programmed death ligand 1 (PD-L1).
  • However, high cost associated with immune checkpoint inhibitors is projected to impede the market growth.
  • The global immune checkpoint inhibitor market is segmented based on type, application, and region.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

Retrieved on: 
Tuesday, November 27, 2018
Medicine, Cancer treatments, Health, Virotherapy, Oncology, Cancer immunotherapy, Cancer, Immunotherapy, Checkpoint inhibitor, Immune system, Active immunotherapy

NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline

Key Points: 
  • NEW YORK, Nov. 27, 2018 /PRNewswire/ -- Global Cancer Immunotherapies Market to 2024 - Increased Uptake of Immune Checkpoint Inhibitors Driving Growth, Supported by a Large, Robust Pipeline
    Cancer immunotherapy, which can predominantly be classed as a form of targeted therapy, drives an immune response against cancer cells.
  • The interest in cancer immunotherapy development has been driven by the growing understanding of the immune system as a hallmark of cancer pathophysiology, particularly immune evasion of developing cancer cells.
  • Overall, 3,863 products are being actively developed in the cancer immunotherapy pipeline, approximately half of the overall oncology pipeline.
  • What molecular targets are most abundant in the pipeline and what role will pipeline product approvals play in market growth?

Curis to Present at the 60th Annual Meeting of the American Society of Hematology

Retrieved on: 
Tuesday, November 20, 2018
IRAK4, Cancer immunotherapy, Oncology

LEXINGTON, Mass., Nov.20, 2018 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology.

Key Points: 
  • LEXINGTON, Mass., Nov.20, 2018 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology.
  • Curis will present three posters at the ASH conference providing key information supporting development of fimepinostat in patients with DLBCL, including patients with MYC-alterations, and CA-4948, Curis's IRAK4 inhibitor, for patients with lymphomas.
  • A pooled analysis of R/R DLBCL patients treated with fimepinostat demonstrates adequate safety and anti-tumor activity supporting the biologic rationale for continued development of fimepinostat in this patient population.
  • Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology.